EFFECT OF ALCOHOLISM ON LIVER FUNCTION TEST IN RURAL POPULATION IN INDIA

Objective: The objective of this study was to evaluate and compare the hepatoprotective effect of clearliv tablets with silymarin in patients with alcoholic liver disease.Methods: This was a prospective, randomized, multicenter, open-label, parallel group interventional clinical endpoint study (Phase IIa). Patients attending general medicine outpatient department were screened for alcoholic liver disease using the serum biochemical liver function test and ultrasonogram abdomen and tested whether they satisfy the selection criteria, and 24 patients were then enrolled in the study. The study drug, namely clearliv tablets of Apex Laboratories Pvt. Ltd., was administered to Group A and tablet silymarin was administered to Group B from day 1 to day 56. Patients were reviewed once in 2 weeks. Liver function test was repeated, and patients were enquired of their well-being and any adverse events.Results: The demographic characters and body weight of the subjects showed no significant difference between the groups. There is a significant improvement (p<0.05) in the aspartate transaminase (AST), alanine transaminase (ALT), and total bilirubin (TB) levels on 28th and 56th days in both silymarin and clearliv groups. Of the 2 groups, there is higher significance of improvement in clearliv group (p<0.001), compared to silymarin group. Clearliv group started showing a significant reduction in AST and ALT levels in the first 14 days of the study period. On comparing the mean percentage reduction in the levels of AST (35.7% and 35%), ALT (26.7% and 24.3%), and TB (26.7% and 25%), it was found that clearliv is showing a better percentage of reduction of the above parameters compared to silymarin. There were reports of adverse effects such as loss of appetite and gastritis in both the groups.Conclusion: This clinical study proves that clearliv is functioning as a hepatoprotective drug. It is offering a better hepatoprotection compared to silymarin. Clearliv tablets can be indicated for the management of liver dysfunction, which occurs due to alcoholic liver damage. It may also be used in similar manner in cases of viral hepatitis, drug-induced liver damage, acute and chronic hepatitis.

Download Full-text

COMPARISON OF LIVER FUNCTION TESTS OF NORMALAND PRE-ECLAMPTIC PREGNANT FEMALES: A HOSPITAL BASED STUDY

10.36106/ijsr/5203593 ◽

2020 ◽

pp. 8-9

Author(s):

Shayista Gull

Keyword(s):

Liver Function ◽

Liver Function Test ◽

Total Protein ◽

Serum Bilirubin ◽

Complete Blood Count ◽

Liver Function Tests ◽

Unknown Etiology ◽

Serum Total Protein ◽

Function Tests ◽

Function Test

Background: Pre-eclampsia is a multi-system disorder of unknown etiology involving almost every organ of body including kidney, liver, brain, heart, stomach and adrenals. In liver periportal hemorrhagic necrosis, ischemic lesions and fibrin deposition occurs due to thrombosis of arterioles. Objective: To compare the liver function tests in normal pregnancy and preeclampsia Methodology: This study was conducted in the Department of Obstetrics and Gynaecology, SKIMS, Soura, Kashmir for 18 months. Participants were divided into two groups: Cases: Comprised of 200 patients with toxemia of pregnancy, Controls: comprised of 500 normal, healthy normotensive pregnant women. This group was studied to get the normal values of liver enzymes and served as controls. A complete blood count, microscopic examination of urine, liver function test, kidney function test , 24 hour urinary protein estimation was done on all participants. Results: Among the cases, 49(24.5%) patients while 76 (15.2%) controls had deranged serum bilirubin. Ninety-nine(49.5%) cases had deranged ALT while 16(3.2%) controls had so. Among the cases, 103(51.5%) had deranged AST level while it was deranged in 64(12.8%) controls. ALP and serum total protein followed similar pattern (more deranged in cases than controls). Conclusion: Liver function test impairment occurs in preeclampsia which is characterized by rise in mean level of serum transaminase levels and serum bilirubin level and fall in serum total protein and albumin level.

Download Full-text

Liver Function Test on HBsAg Positive Blood Donors

Tribhuvan University Journal of Microbiology ◽

10.3126/tujm.v4i0.21668 ◽

2018 ◽

Vol 4 ◽

pp. 9-10 ◽

Cited By ~ 1

Author(s):

Amrit MS Maharjan ◽

Bharat Jha ◽

Anjana Singh

Keyword(s):

Hepatitis B ◽

Liver Function ◽

Liver Function Test ◽

Blood Donors ◽

Hepatitis B Surface Antigen ◽

Albumin Level ◽

Normal Range ◽

Serum Samples ◽

B Virus ◽

Function Test

Objectives: The study was done to assess liver function test among hepatitis B surface antigen (HBsAg) positive blood donors.Methods: Liver function test (LFT) were studied in 71 HBsAg positive serum samples from healthy blood donors.Results: In the study, 14(19.7Ü) serum samples showed elevated alanine aminotransferase (ALT) level above the normal range (5_35 IU/I) with mean 66.3±27.6; 16(22.5%) showed aspartate aminotransferase (AST) level above the normal range (5-40 IU/I) with mean 87.5±35.7; 4(5.6%) serum samples showed alkaline phosphatase (ALP) level above the normal range (306 IU/I) with mean 376.5±31.5; 49(69%) samples were found to be below the normal albumin level (38-51gm/I) with mean 23.9±5.76.Conclusion: Deviations in the serum enzymes (ALT, AST and ALP) as well as total protein and albumin level showed the silent infection of hepatitis B virus in healthy blood donors.

Download Full-text

Measurement of Total Protein Is Not a Useful Inclusion in Liver Function Test Profiles

Clinical Chemistry ◽

10.1093/clinchem/46.7.1022a ◽

2000 ◽

Vol 46 (7) ◽

pp. 1022-1023 ◽

Cited By ~ 4

Author(s):

Bhoji Watts ◽

Leslie Burnett ◽

Doug Chesher

Keyword(s):

Liver Function ◽

Liver Function Test ◽

Total Protein ◽

Function Test ◽

Test Profiles

Download Full-text

Measurement of Total Protein Is a Useful Inclusion in Liver Function Test Profiles

Clinical Chemistry ◽

10.1093/clinchem/47.4.793 ◽

2001 ◽

Vol 47 (4) ◽

pp. 793-794 ◽

Cited By ~ 6

Author(s):

Katharine Hayden ◽

Charles van Heyningen

Keyword(s):

Liver Function ◽

Liver Function Test ◽

Total Protein ◽

Function Test ◽

Test Profiles

Download Full-text

A RANDOMIZED CLINICAL ENDPOINT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CLEARLIV TABLETS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v12i1.29921 ◽

2019 ◽

Vol 12 (1) ◽

pp. 297

Author(s):

Ramesh Kannan S ◽

Sivaraman V ◽

Mirunalini C ◽

Sakthibalan M ◽

Jayashree S ◽

...

Keyword(s):

Liver Disease ◽

Liver Function ◽

Liver Function Test ◽

Liver Damage ◽

Alcoholic Liver Disease ◽

Well Being ◽

Study Phase ◽

Clinical Endpoint ◽

Significant Difference ◽

Function Test

Objective: The objective of this study was to evaluate and compare the hepatoprotective effect of clearliv tablets with silymarin in patients with alcoholic liver disease.Methods: This was a prospective, randomized, multicenter, open-label, parallel group interventional clinical endpoint study (Phase IIa). Patients attending general medicine outpatient department were screened for alcoholic liver disease using the serum biochemical liver function test and ultrasonogram abdomen and tested whether they satisfy the selection criteria, and 24 patients were then enrolled in the study. The study drug, namely clearliv tablets of Apex Laboratories Pvt. Ltd., was administered to Group A and tablet silymarin was administered to Group B from day 1 to day 56. Patients were reviewed once in 2 weeks. Liver function test was repeated, and patients were enquired of their well-being and any adverse events.Results: The demographic characters and body weight of the subjects showed no significant difference between the groups. There is a significant improvement (p<0.05) in the aspartate transaminase (AST), alanine transaminase (ALT), and total bilirubin (TB) levels on 28th and 56th days in both silymarin and clearliv groups. Of the 2 groups, there is higher significance of improvement in clearliv group (p<0.001), compared to silymarin group. Clearliv group started showing a significant reduction in AST and ALT levels in the first 14 days of the study period. On comparing the mean percentage reduction in the levels of AST (35.7% and 35%), ALT (26.7% and 24.3%), and TB (26.7% and 25%), it was found that clearliv is showing a better percentage of reduction of the above parameters compared to silymarin. There were reports of adverse effects such as loss of appetite and gastritis in both the groups.Conclusion: This clinical study proves that clearliv is functioning as a hepatoprotective drug. It is offering a better hepatoprotection compared to silymarin. Clearliv tablets can be indicated for the management of liver dysfunction, which occurs due to alcoholic liver damage. It may also be used in similar manner in cases of viral hepatitis, drug-induced liver damage, acute and chronic hepatitis.

Download Full-text